Susceptibility to Aflatoxin B 1-related Primary Hepatocellular Carcinoma in Mice and Humans

The genetic basis of disease susceptibility can be studied by several means, including research on animal models and epidemiological investigations in humans. The two methods are infrequently used simultaneously, but their joint use may overcome the disadvantages of either method alone. We used both approaches in an attempt to understand the genetic basis of aflatoxin B1 (AFB1)-related susceptibility to hepatocellular carcinoma (HCC). Ingestion of AFB1 is a major risk factor for HCC in many areas of the world where HCC is common. Whether humans vary in their ability to detoxify the active intermediate metabolite of AFB1, AFB1-exo-8,9-epoxide, is not certain but may explain why all exposed individuals do not develop HCC. To determine whether human variability in detoxification may exist, in a study of 231 HCC cases and 256 controls, we genotyped eleven loci in two families of AFB1 detoxification genes; the glutathione S-transferases (GSTs) and the epoxide hydrolases (EPHX). After adjustment for multiple comparisons, only one polymorphism in the epoxide hydrolase family 2 locus remained significantly associated with HCC (odds ratio 2.06, 95% confidence interval 1.13–3.12). To determine whether additional susceptibility loci exist, we developed a mouse model system to examine AFB1-induced HCC. Susceptibility of 7-day-old mice from two common inbred strains (C57BL/6J, DBA/2J) was assessed. DBA/2J animals were 3-fold more sensitive to AFB1-induced HCC and significantly more sensitive to AFB1 acute toxicity than were C57BL/6J animals. Analysis of the xenobiotic metabolizing genes in the two strains revealed single nucleotide polymorphisms in three genes, Gsta4, Gstt1, and Ephx1. Although the GSTT1 and EPHX1 loci did not appear to be related to HCC in the total population of the human study, a polymorphism in GSTA4 was significantly related to risk in the male subset. The mouse model also demonstrated that absent or compromised p53 was not necessary for the development of carcinogenesis. These results indicate that the comparison of results from human studies and the AFB1-susceptible mouse model may provide new insights into hepatocarcinogenesis.

[1]  S. Thorgeirsson,et al.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China , 2002, Hepatology.

[2]  A J Hall,et al.  Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study , 2002, BMJ : British Medical Journal.

[3]  D. Kroetz,et al.  Cytochrome P450 pathways of arachidonic acid metabolism , 2002, Current opinion in lipidology.

[4]  W. Tsai,et al.  Polycyclic aromatic hydrocarbon‐DNA adducts in liver tissues of hepatocellular carcinoma patients and controls , 2002, International journal of cancer.

[5]  W. London,et al.  Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  B Budowle,et al.  STR primer concordance study. , 2001, Forensic science international.

[7]  W. Longstreth,et al.  Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease. , 2001, Pharmacogenetics.

[8]  J. Fraumeni,et al.  International trends and patterns of primary liver cancer , 2001, International journal of cancer.

[9]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[10]  C. J. Chen,et al.  Variability in aflatoxin-albumin adduct levels and effects of hepatitis B and C virus infection and glutathione S-transferase M1 and T1 genotype. , 2001, Environmental health perspectives.

[11]  C. J. Chen,et al.  Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. , 2001, Carcinogenesis.

[12]  P. van’t Veer,et al.  Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  W. Tsai,et al.  Associations of Plasma Aflatoxin B1-Albumin AdductLevel With Plasma Selenium Level and GeneticPolymorphisms of Glutathione S-Transferase M1 and T1 , 2000, Nutrition and cancer.

[14]  Xiao-hong Wang,et al.  Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. , 2000, World journal of gastroenterology.

[15]  C. Smith,et al.  Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. , 2000, Toxicology letters.

[16]  H. Whittle,et al.  Environmental and genetic determinants of aflatoxin–albumin adducts in The Gambia , 2000, International journal of cancer.

[17]  C. J. Chen,et al.  Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. , 1999, American journal of epidemiology.

[18]  Michael N. Edmonson,et al.  Reliable identification of large numbers of candidate SNPs from public EST data , 1999, Nature Genetics.

[19]  M. Sekijima,et al.  Fumonisins as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[20]  T. Dragani,et al.  Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis. , 1997, Carcinogenesis.

[21]  L W Wang,et al.  Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. , 1996, American journal of human genetics.

[22]  C. J. Chen,et al.  L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. , 1996, Cancer letters.

[23]  C. J. Chen,et al.  Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. , 1995, Gastroenterology.

[24]  N. Drinkwater,et al.  The Hcr (hepatocarcinogen resistance) loci of DBA/2J mice partially suppress phenotypic expression of the Hcs (hepatocarcinogen sensitivity) loci of C3H/HeJ mice. , 1995, Carcinogenesis.

[25]  K. Buetow,et al.  Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Gariboldi,et al.  Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. , 1994, Genomics.

[27]  J. S. Sidhu,et al.  Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. , 1994, Human molecular genetics.

[28]  H. Whittle,et al.  Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  R. Holubkov,et al.  Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. , 1993, Pharmacogenetics.

[30]  M. Gariboldi,et al.  Chromosome mapping of murine susceptibility loci to liver carcinogenesis. , 1993, Cancer research.

[31]  D. Slone,et al.  Comparison of the aflatoxin B1-8,9-epoxide conjugating activities of two bacterially expressed alpha class glutathione S-transferase isozymes from mouse and rat. , 1992, Biochemical and biophysical research communications.

[32]  T. Dragani,et al.  Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. , 1991, Cancer research.

[33]  T. Rushmore,et al.  Protective activity of different hepatic cytosolic glutathione S-transferases against DNA-binding metabolites of aflatoxin B1. , 1990, Toxicology and applied pharmacology.

[34]  N. Drinkwater,et al.  Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. , 1986, Carcinogenesis.

[35]  J. Miller,et al.  Base substitution mutations induced by metabolically activated aflatoxin B1. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Wogan,et al.  Aflatoxin B 1 , a hepatocarcinogen in the infant mouse. , 1972, Cancer research.

[37]  J. Miller,et al.  Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. , 1972, Cancer research.

[38]  P. van’t Veer,et al.  Peanut butter intake, GSTM1 genotype and hepatocellular carcinoma: a case–control study in Sudan , 2004, Cancer Causes & Control.

[39]  D. Eaton,et al.  Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in aflatoxin B1 detoxification. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  G. -. Lee,et al.  Identification of hepatocarcinogen-resistance genes in DBA/2 mice. , 1995, Genetics.

[41]  K. Buetow,et al.  Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. , 1995, Intervirology.

[42]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.

[44]  G. Wogan.  CHAPTER VI – METABOLISM AND BIOCHEMICAL EFFECTS OF AFLATOXINS , 1969 .

[45]  L. A. Goldblatt.  Aflatoxin. Scientific background, control, and implications. , 1969 .